$SLP

Simulations Plus, Inc.

0
1
2
—
$63.2M
FREDERICK WILLIAM W
0%
See all $SLP insider activity →
Low

Simulations Plus Announced Transfer or Voluntary Withdrawal of Listing

Simulations Plus (SLP) requested delisting from Nasdaq and deregistration of its common shares, effective October 6, 2026, following a merger. The company also plans to terminate SEC reporting obligations. According to the company's SEC filing, trading of its shares ceased on that date.

Simulations Plus, Inc. (SLP): Completion of Acquisition or Disposition of Assets

Simulations Plus, Inc. (SLP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 1 Exhibit 99.1 Simulations Plus Announces Completion of Acquisition by Altaris RESEARCH TRIANGLE PARK, NC, October 6, 2026 – Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that adva

SLP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning SLP (Simulations Plus, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 2 bearish.

Recent SLP coverage spans insider activity, mergers & acquisitions and corporate actions.

In the last 30 days, SLP insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($63.2M). The most active reporter was FREDERICK WILLIAM W, EVP/CFO, with 1 filing.

What's driving SLP

AlphAI scores every news story that mentions SLP with an AI model for sentiment and relevance, and aggregates insider trades from Simulations Plus, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SLP

Score

Simulations Plus, Inc. (SLP): Completion of Acquisition or Disposition of Assets

Simulations Plus, Inc. (SLP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 1 Exhibit 99.1 Simulations Plus Announces Completion of Acquisition by Altaris RESEARCH TRIANGLE PARK, NC, October 6, 2026 – Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that adva

Related tickers